Results 11 to 20 of about 1,925 (192)

Administration of Nirsevimab for RSV Prophylaxis in Infants: A Comprehensive Review

Vaccines
Respiratory syncytial virus (RSV) is the primary etiological agent responsible for lower respiratory tract infections (LRTIs) and hospitalizations among infants. Nirsevimab, a novel monoclonal antibody (mAb), offers sustained protection against RSV for a
Pan-Pan Wu, Fang-Rui Ding
doaj   +4 more sources

Effectiveness of Nirsevimab Immunoprophylaxis Administered at Birth to Prevent Infant Hospitalisation for Respiratory Syncytial Virus Infection: A Population-Based Cohort Study

Vaccines
Respiratory syncytial virus (RSV) infection is a frequent cause of hospitalisation in the first few months of life; however, this risk rapidly decreases with age.
Ana Navascues, Natividad Viguria, Juan C Muruzabal   +2 more
exaly   +4 more sources

Molecular and phenotypic characteristics of RSV infections in infants during two nirsevimab randomized clinical trials

Nature Communications, 2023
Nirsevimab is a monoclonal antibody that binds to the respiratory syncytial virus (RSV) fusion protein. During the Phase 2b (NCT02878330) and MELODY (NCT03979313) clinical trials, infants received one dose of nirsevimab or placebo before their first RSV ...
Bahar Ahani, Kevin M. Tuffy, Anastasia A. Aksyuk, Deidre Wilkins, Michael E. Abram, Ron Dagan, Joseph B. Domachowske, Johnathan D. Guest, Hong Ji, Anna Kushnir, Amanda Leach, Shabir A. Madhi, Vaishali S. Mankad, Eric A. F. Simões, Benjamin Sparklin, Scott D. Speer, Ann Marie Stanley, David E. Tabor, Ulrika Wählby Hamrén, Elizabeth J. Kelly, Tonya Villafana   +20 more
doaj   +2 more sources

Multicentre study on nirsevimab: Bayesian analysis reveals persisting risk for preterm infants [PDF]

BMJ Paediatrics Open
Objective To evaluate whether the timing and effectiveness of nirsevimab prophylaxis vary by gestational age.Design Retrospective cohort study conducted during two identical epidemic seasons: 2023–2024 (before nirsevimab introduction) and 2024–2025 ...
Federico Marchetti, Enrico Valletta, Gianluca Vergine, Silvia Bloise, Gina Ancora, Enrico Cocchi, Aurora Lorefice, Sara Zannoni, Benedetta Pellegrini, Francesco Saverio Morlupo, Beatrice Scarpellini, Melodie Olivia Loredana Rosa Aricò, Francesco Accomando, Marcello Stella   +13 more
doaj   +2 more sources

Fc-mediated functions of nirsevimab complement direct respiratory syncytial virus neutralization but are not required for optimal prophylactic protection [PDF]

Frontiers in Immunology, 2023
IntroductionNirsevimab is an extended half-life (M252Y/S254T/T256E [YTE]-modified) monoclonal antibody to the pre-fusion conformation of the respiratory syncytial virus (RSV) Fusion protein, with established efficacy in preventing RSV-associated lower ...
Tyler Brady, Corinne Cayatte, Tiffany L. Roe, Scott D. Speer, Hong Ji, LeeAnn Machiesky, Tianhui Zhang, Deidre Wilkins, Kevin M. Tuffy, Elizabeth J. Kelly   +9 more
doaj   +2 more sources

A phase I, randomized, placebo‐controlled trial to evaluate the pharmacokinetics, safety, and tolerability of nirsevimab in healthy Chinese adults

Clinical and Translational Science
Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infection (LRTI) in infants worldwide. Nirsevimab, an extended half‐life monoclonal antibody against RSV, is approved in China for the prevention of RSV lower respiratory ...
Xiaomeng Mao, Xiaohan Hua, Chengyi Wu, Xiaoyun Ge, Jie Zhang, Xiaojie Wu, Robert J. Kubiak, Ulrika Wählby Hamrén, Tonya Villafana, Georgios Christou, Jannine Green, Therese Takas, Yuwen Jin   +12 more
doaj   +2 more sources

The efficacy and safety of nirsevimab for the prevention of RSV infection among infants: A systematic review and meta-analysis [PDF]

Frontiers in Pediatrics, 2023
BackgroundRespiratory syncytial virus (RSV) is a leading cause of morbidity and mortality among infants with a global incidence of 9.5% and a mortality rate of 2.2%. The management of RSV infection is mainly supportive and, aside from emerging monoclonal
Maria Wilma R. Turalde-Mapili, Jerahmeel Aleson L. Mapili, Christian Wilson R. Turalde, Christian Wilson R. Turalde, Marimel R. Pagcatipunan   +4 more
doaj   +2 more sources

Nirsevimab Treatment of RSV Bronchiolitis in Pediatric Emergency Departments

JAMA Network Open
Importance New resistant mutations of respiratory syncytial virus type B (RSV-B) have been observed during the first year of implementation nirsevimab treatment. During the second season of implementation of nirsevimab treatment in France, RSV-B was predominant.
Lenglart, Lea, Levy, Corinne, Basmaci, Romain, Levieux, Karine, Kramer, Rolf, de Mari, Pauline, Béchet, Stéphane, Launay, Elise, Perceval, Lise, Cohen, Laure, Aupiais, Camille, de Pontual, Loic, Rybak, Alexis, Ouldali, Naim, Cohen, Robert   +14 more
openaire   +4 more sources

Real-world effectiveness of nirsevimab against respiratory syncytial virus in pediatric practice: the Piemonitorab study [PDF]

Italian Journal of Pediatrics
Background Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections (LRTIs) in pediatric populations, resulting in a substantial burden of disease.
Elisa Funiciello, Alessia Spadavecchia, Celeste Cagnazzo, Lorenza Ferrara, Bartolomeo Griglio, Antonino Sottile, Paola Berchialla, Franca Fagioli, on behalf of the Piemonitorab Study Group   +8 more
doaj   +2 more sources

Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants

New England Journal of Medicine, 2020
Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infection in infants, and a need exists for prevention of RSV in healthy infants. Nirsevimab is a monoclonal antibody with an extended half-life that is being developed to protect infants for an entire RSV season with a single intramuscular dose.In this trial ...
M Pamela Griffin, Thérèse Takas, Joseph B Domachowske   +2 more
exaly   +6 more sources